Exyte, a global leader in the design, engineering, and delivery of high-tech facilities, intends to acquire TTP Group (TTP), a leading firm in consulting and engineering for the pharmaceutical and chemical industry in Europe. 

TTP's portfolio encompasses a wide range of engineering services, from feasibility studies, basic and detailed engineering, to construction management, as well as commissioning, qualification, and validation services. 

Exyte and the financial investor Robus Capital along with minority shareholders of TTP have signed the respective definite agreements. The purchase price has been agreed to remain confidential. The transaction is subject to the necessary regulatory approvals. 

TTP is a specialized and a trusted partner for blue-chip clients in the biotech, pharma and chemical industries in Europe. The company, through its two operational brands 'Pharmaplan' and 'Triplan,' covers the entire service spectrum from Engineering to Procurement, Construction Management, and Validation. 

"By combining TTP's engineering expertise with Exyte's project execution capabilities, we will establish a robust presence in the biotech and pharma sector in Europe. This will enable us to offer clients the full range of collaboration, from strategic planning to the delivery of biotechnology and pharma facilities. With the planned acquisition, Exyte expands its position as a global player in the pharma market, strengthening its footprint in Europe. TTP's employees are experienced and specialized experts, including engineers, architects, and project managers. Their expertise and innovative spirit will make a significant contribution to Exyte's sustainable, profitable growth. We look forward to welcoming them soon to the Exyte team," says Dr. Wolfgang Büchele, CEO of Exyte. 

"TTP and Exyte share the same values and the ambition to offer innovative and sustainable solutions to their customers. Together, we will continue our growth trajectory in the booming pharmaceutical facilities market. The combination of our strengths is a positive signal for our customers. We look forward to a shared future with Exyte," says Dr. Andreas Bonhoff, CEO of the TTP Group.